Role of Clomiphene Citrate Treatment in Subfertility Due to Polycystic Ovarian Syndrome

  • Mehviah Javeria Senior Registrar CIMS Multan
  • Nida Qayyum Classified Derma CMH, Multan
  • Qurat Ul Ain Hanif Classified Gynae, CMH Quetta
  • Samar Hussain Assistant Professor, Gynecologist, Rashid Latif Medical College, Lahore
  • Sadia Majeed Classified Gynecologist, CMH Multan
  • Muhammad Azam Classified pathology, CMH Multan


Objective: To assess the frequency of mature follicle rate as a result of clomiphene citrate treatment in subfertility due to polycystic ovarian syndrome.

Methodology: This descriptive cross-sectional study was conducted at Obstetrics and Gynecology department, CMH (Combined Military Hospital), Multan, for 6 months from 1st March to 1st September 2023. The study comprised of 373 cases aged between 20–40 years reporting infertility for longer than a year, having body mass index <28, and having subfertility owing to PCOS. All study participants were subjected to clomiphene citrate treatment. Each woman continued to receive metformin 500 mg thrice a day. Development of mature follicles was observed utilizing transvaginal ultrasound from 10th day onwards.

Results: Of 373 females the mean age of patients was 32.07±4.22 years. Mean weight of the patients was 59.54 ± 6.05 kg whereas the mean height was 1.61 ± 0.067 m. Mean body mass index (BMI) was 22.92 ± 2.28 kg/m². 203(54.4%) patients had primary while 170 (45.6%) had secondary infertility. 128(34.32%) patients had mature follicles on ultrasonography after receiving clomiphene citrate treatment.

Conclusion: It was concluded that patients receiving clomiphene citrate treatment had acceptable number of mature follicles, thereby likely increasing pregnancy rates in women with PCOS.

Original Articles